verified SJR 1,034 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Taylor and Francis Ltd.

workspace_premium Q1 — Pharmacology lock Subscription

Expert Opinion on Emerging Drugs

Expert Opinion on Emerging Drugs is a journal indexed in SJR in Pharmacology and Pharmacology (medical) with an H index of 58. It has a price of 4000 €. It has an SJR impact factor of 1,034 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,034.

ISSN: 1472-8214

Publisher: Taylor and Francis Ltd.

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,034 Q1

H-index 58

Acceptance rate pie_chart

30% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

4.000 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,034

H-index

Docs (year)

Docs 3y

Total refs

2938

Cites 3y

224

Citable 3y

Cites/Doc 2y

2.22

Ref/Doc

89.03

Immediate OA

4000 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Emerging angiogenesis inhibitors for non-small cell lung cancer

What role do pharmaceuticals play in the treatment of Peyronie's disease and is there a need for new emerging drugs?

Emerging drugs for diabetic foot ulcers

Emerging drugs for Cushing's disease

Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises

Emerging drugs for colorectal cancer

Emerging drugs for chronic urticaria

Emerging drugs for asthma

Emerging drugs for adult acute lymphoblastic leukaemia

Emerging drugs for acute and chronic heart failure: current and future developments

Emerging drug treatments for cystic fibrosis

Emerging drug for diarrhea predominant irritable bowel syndrome

SHOW MORE ARTICLES

Emerging azole antifungals

ADP receptor antagonists as antiplatelet therapeutics

Emerging analgesics in cancer pain management

Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia

DNA vaccination

Current and emerging therapies for the lysosomal storage disorders

Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

Bisphosphonate therapy in the oncology setting

Antiviral activity of 4-benzyl pyridinone derivatives as HIV-1 reverse transcriptase inhibitors

Antithrombotic agents in the treatment of severe sepsis

An update on emerging drugs for Hodgkin lymphoma

Advances in pharmacotherapy for tobacco dependence

FAQs

Expert Opinion on Emerging Drugs has an SJR of 1,034 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 4000 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Expert Opinion on Emerging Drugs is 30%.

Expert Opinion on Emerging Drugs

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Expert Opinion on Emerging Drugs?

What is the APC / publication cost?

What is the acceptance rate?